David R. Liu - 24 Oct 2022 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role: 10%+ Owner
Signature: /s/ Carman Alenson attorney-in-fact
Issuer symbol: PRME
Transactions as of: 24 Oct 2022
Net transactions value: $0
Form type: 4
Filing time: 26 Oct 2022, 20:00:53 UTC
Previous filing: 19 Oct 2022
Next filing: 26 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRME	Common Stock	Conversion of derivative security		+321,665	+1.5%		21,156,945	24 Oct 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRME	Series A Convertible Preferred Stock	Conversion of derivative security	$0	-1,000,001	-100%	$0.000000^*	0	24 Oct 2022	Common Stock	321,665		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date.

Content

The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date.